BRCA1 and gastric cancer: Despite this increased risk, there are no recommendations for gastric surveillance in BRCA1/2 PV carriers, although if a carrier does develop a BRCA1/2-related gastric cancer, these individuals may be eligible for specific therapy such as poly ADP ribose polymerase (PARP) inhibitors170.